Investor Relations

Gelteq specialises in the formulation, development and manufacturing of edible gel products utilising our patented, gel-based oral drug delivery system. We are dedicated to delivering products that contribute to the commercial success of our partners whilst also improving the overall health of people.

Our primary focus is on advancing the application of our gel-based drug delivery system. We strive to maintain the simplicity, accessibility, and efficacy of oral delivery while eliminating the traditional impediments associated with other methods.

As Gelteq continues to grow, we are exploring opportunities to further the application of our revolutionary gel technology in the pharmaceuticals, pet and veterinary, nutrition, and sports performance sectors. These ventures are aimed at maximizing the potential and use-case of our products, thus creating value for both investors and consumers.

Stock Snapshot

Latest Financial Results

FY 2024

Fiscal Year Ended Jun 30, 2024

Latest Annual Filing

For Fiscal Year Ending Jun 30, 2024

Company Overview

Founded in 2017, the idea for Gelteq was born out of the necessity for a practical delivery method for individuals facing difficulties with swallowing, known as dysphagia. These challenges in swallowing can result in patients not adhering to their treatment plans, leading to potential long-term health complications.

Our expertise lies in formulating, developing, and manufacturing products using our patented, gel-based oral drug delivery system. Gels address numerous drawbacks commonly associated with oral delivery methods, such as swallowing difficulties, taste issues, and concerns about dosage and effectiveness.

At Gelteq, our primary focus centers on thriving markets where our technology can make a genuine impact. The pharmaceutical, nutraceutical, and animal health sectors all stand to gain significant benefits from our gel-based delivery systems.

IR Contacts

Company

Gelteq Limited
Level 4
100 Albert Road
South Melbourne, VIC 3025
Australia
T: +61 3 9087 3990
info@gelteq.com

Investor Relations

Gelteq
Simon Szewach
Executive Chairman
641 Glenhuntly Road
Caulfield, VIC 3162
Australia
T: +61 3 9087 3990
Simon@gelteq.com
https://www.gelteq.com


CoreIR
Chuck Bennett
CEO
377 Oak Street
Level 2 Garden City
New York, NY 11530
United States
T: +1 212 655 0924
Cb@coreir.com

Transfer Agent

Colonial Stock Transfer Co, Inc.
Kalysha Chandler
7840 S 700 E
Sandy, UT 84070
United States
T: 801-355-5740
Kalyshachandler@colonialstock.com
https://www.colonialstock.com